Introduction: Cutaneous Rosai-Dorfman disease is a rare form of histiocytosis. There are no established standards for its treatment, and some patients have minimal or no response. To date, no published reports have described disease progression in cutaneous Rosai-Dorfman disease in relation to specific treatment modalities. Material and methods: The patients were examined at the Department of Dermatology of the Dr. Bogomolets Institute of Dermatology and Cosmetology in Kyiv, Ukraine. Ultrasound imaging was performed using a linear transducer. Dermoscopy was performed using a digital video dermatoscope. Formalin-fixed paraffin-embedded tissue samples were processed using standard protocols. Qualitative assessment of tissue morphology was performed using commercially available Series S histological stains (Epredia, Kalamazoo, MI, USA). Immunohistochemical staining was carried out using a ready-to-use anti-S100 antibody. A literature search was conducted via PubMed using the keyword combination 'cutaneous Rosai-Dorfman disease'. Results: Two cases of cutaneous Rosai-Dorfman disease in Caucasian female patients are reported. One patient exhibited disease exacerbation following rapid tapering of systemic corticosteroids and another one after exposure to doxycycline. Diagnosis was confirmed by histopathologic evaluation and S100-positive immunohistochemical staining. Conclusions: Further clinical studies on the treatment of cutaneous Rosai-Dorfman disease, including data on therapeutic outcomes (complete and partial responses) and treatment-related exacerbations, are needed to optimize clinical management and improve patient outcomes.